Catheter Precision Inc

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catheter Precision, Inc. engages in the design, manufacture and sale of medical devices and technologies for cardiac electrophysiology. It offers the Amigo Remote Catheter System for accurate positioning, manipulation, and stable control of catheters for use by electrophysiologists in the diagnosis and treatment of abnormal heart rhythms. The company was founded by David Jenkins in September 2002 and is headquartered in Fort Mill, SC.

The National Health System England Grants VIVO™ Additional Reimbursement FORT MILL, SC / ACCESSWIRE / October 12, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announces that its VIVO 3D mapping system has been granted national reimbursement in the UK after inclusion in the High-Coast Tariff Excluded Devices (HCTED). VIVO enables physicians to identify the origin of ventricular arrhythmias pre-procedure, streamlining workflow and reducing procedure time.

Catheter Precision's VIVO is Now Eligible for National Reimbursement in the UK

VIVO to Be Highlighted at Several Electrophysiology Conferences FORT MILL, SC / ACCESSWIRE / October 10, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK) announced that its innovative 3D Mapping system will be highlighted at several electrophysiology conferences this fall. Most recently, VIVO was highlighted at the 19th Congresso Nazionale Associazione Italiana di Aritmologia e Cardiostimolazione in Bologna, Italy from September 21-22.

Catheter Precision Showcasing its Innovative 3D Mapping System

Management Presentation on September 11, 2023 at 7:00 am ET FORT MILL, SC / ACCESSWIRE / September 7, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) announced today that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11 - 13th.

Catheter Precision, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

FORT MILL, SC / ACCESSWIRE / August 31, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK) announced that the Company entered a distribution partnership with Somnotec (S) Pte Ltd., a medical device distributor based in Singapore.

Catheter Precision Secures New Distribution Partner for Southeast Asia

FORT MILL, SC / ACCESSWIRE / August 25, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK) announced today that on August 22, 2023, the Company received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American (the "Exchange") under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide (the "Company Guide"). The non-compliance results from the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the "Delinquent Report") by the extended filing due date of August 21, 2023 (the "Filing Delinquency").

Catheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q

Ra Medical Systems Inc

New Symbol VTAK to be Effective as of Friday Morning Opening FORT MILL, SC / ACCESSWIRE / August 18, 2023 / Catheter Precision, Inc., (NYSE American:VTAK), the renamed company that previously was named Ra Medical Systems, Inc., will now be trading under the symbol VTAK. VTAK is an anachronym for Ventricular Tachyarrhythmia, also called VT, a fast heartbeat of the ventricle.

RMED Symbol Now Changed to VTAK

News for Catheter Precision Inc Stock (VTAK)